Export this Abstract | Print this Abstract | Add to my preferred Abstracts list | My preferred Abstracts list (6) | Back to Search
NIVOLUMAB-INDUCED FULMINANT TYPE 1 DIABETES
- At: AbuDhabi (United Arab Emirates) (2019)
- Type: Poster
- Poster code: POS-HPS-103
- By: MORGADO, Manuel (University of Beira Interior, Health Science Faculty, Portugal)
- Co-author(s): Carolina Lopes: Health Science Faculty, University of Beira Interior, Covilhã, Portugal
Ema Paulino: Portuguese Pharmaceutical Society, Lisbon, Portugal
Sandra Morgado: Pharmaceutical Services, University Hospital Center of Cova da Beira, Covilhã, Portugal
Manuel Morgado: Pharmaceutical Services, University Hospital Center of Cova da Beira, Covilhã, Portugal;Health Science Faculty, University of Beira Interior, Covilhã, Portugal;School of Health Sciences, Polytechnic Institute of Guarda, Guarda, Portugal - Abstract:
Background
Nivolumab is an immune checkpoint inhibitor (ICI) that binds and blocks the activation of PD-1’s receptor, reactivating T cells and cell-mediated immune responses. Fulminant type 1 diabetes (FD) is an immune endocrinopathy resulting from a violent immune attack which leads to complete destruction of pancreatic β-cells. FD can happen as.. The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress.
Please login
Last update 28 September 2023